17-Jan-2025
Cybin Partners with Segal Trials for Pivotal Phase 3 Program
TipRanks (Wed, 15-Jan 12:38 PM ET)
Cybin enters partnership agreement to conduct phase 3 trial for depression candidate
Seeking Alpha News (Wed, 15-Jan 12:32 PM ET)
Business Wire (Wed, 15-Jan 12:07 PM ET)
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Business Wire (Mon, 13-Jan 7:30 AM ET)
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Business Wire (Thu, 9-Jan 5:00 PM ET)
Business Wire (Tue, 10-Dec 7:30 AM ET)
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Business Wire (Wed, 4-Dec 7:30 AM ET)
Business Wire (Mon, 18-Nov 7:00 AM ET)
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Business Wire (Thu, 14-Nov 7:30 AM ET)
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
Cybin Common Shares trades on the AMEX stock market under the symbol CYBN.
As of January 17, 2025, CYBN stock price climbed to $9.13 with 163,503 million shares trading.
CYBN has a market cap of $182.53 million. This is considered a Micro Cap stock.
In the last 3 years, CYBN traded as high as $13.88 and as low as $.17.
The top ETF exchange traded funds that CYBN belongs to (by Net Assets): IBB, PSIL.
CYBN has outperformed the market in the last year with a return of +2296.3%, while the SPY ETF gained +28.0%. However, in the most recent history, CYBN shares have underperformed the stock market with its stock returning -12.6% in the last 3 month period and -9.6% for the last 2 week period, while SPY has returned +3.0% and +1.0%, respectively.
CYBN support price is $8.57 and resistance is $9.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYBN shares will trade within this expected range on the day.